Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)

Rafael Valencia, Matthew J. Price, Neil Sawhney, Steve S. Lee, Garrett B Wong, Raghava R. Gollapudi, Michelle Banares, Richard A. Schatz, Paul S. Teirstein

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide alone or eptifibatide plus UFH. Patients received aspirin 325 mg and clopidogrel 300 mg before the procedure. The primary end point was the Landefeld bleeding index. Secondary end points included the composite clinical outcome of in-hospital death, myocardial infarction, urgent target vessel revascularization, and Thrombolysis In Myocardial Infarction major bleeding, and a composite bleeding outcome of major, minor, and nuisance bleeding. The Landefeld bleeding index was significantly lower in the eptifibatide-only group compared with the eptifibatide-plus-UFH group (3.0 vs 3.9, p = 0.03). There was no significant difference in the composite clinical end point between groups (eptifibatide only 17% vs eptifibatide plus UFH 15%, p = 0.7). There was a trend toward a decrease in the composite bleeding end point in the eptifibatide-only compared with the eptifibatide-plus-UFH group (43% vs 56%, p = 0.10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications.

Original languageEnglish (US)
Pages (from-to)1099-1102
Number of pages4
JournalAmerican Journal of Cardiology
Volume100
Issue number7
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Hemorrhage
Safety
clopidogrel
Heparin
Aspirin
Platelet Glycoprotein GPIIb-IIIa Complex
Therapeutics
Myocardial Infarction
eptifibatide
Anticoagulants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial). / Valencia, Rafael; Price, Matthew J.; Sawhney, Neil; Lee, Steve S.; Wong, Garrett B; Gollapudi, Raghava R.; Banares, Michelle; Schatz, Richard A.; Teirstein, Paul S.

In: American Journal of Cardiology, Vol. 100, No. 7, 01.10.2007, p. 1099-1102.

Research output: Contribution to journalArticle

Valencia, Rafael ; Price, Matthew J. ; Sawhney, Neil ; Lee, Steve S. ; Wong, Garrett B ; Gollapudi, Raghava R. ; Banares, Michelle ; Schatz, Richard A. ; Teirstein, Paul S. / Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial). In: American Journal of Cardiology. 2007 ; Vol. 100, No. 7. pp. 1099-1102.
@article{3580d0fbe3bb4177a5774e1bd5ff8e32,
title = "Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)",
abstract = "Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide alone or eptifibatide plus UFH. Patients received aspirin 325 mg and clopidogrel 300 mg before the procedure. The primary end point was the Landefeld bleeding index. Secondary end points included the composite clinical outcome of in-hospital death, myocardial infarction, urgent target vessel revascularization, and Thrombolysis In Myocardial Infarction major bleeding, and a composite bleeding outcome of major, minor, and nuisance bleeding. The Landefeld bleeding index was significantly lower in the eptifibatide-only group compared with the eptifibatide-plus-UFH group (3.0 vs 3.9, p = 0.03). There was no significant difference in the composite clinical end point between groups (eptifibatide only 17{\%} vs eptifibatide plus UFH 15{\%}, p = 0.7). There was a trend toward a decrease in the composite bleeding end point in the eptifibatide-only compared with the eptifibatide-plus-UFH group (43{\%} vs 56{\%}, p = 0.10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications.",
author = "Rafael Valencia and Price, {Matthew J.} and Neil Sawhney and Lee, {Steve S.} and Wong, {Garrett B} and Gollapudi, {Raghava R.} and Michelle Banares and Schatz, {Richard A.} and Teirstein, {Paul S.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.amjcard.2007.04.057",
language = "English (US)",
volume = "100",
pages = "1099--1102",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial)

AU - Valencia, Rafael

AU - Price, Matthew J.

AU - Sawhney, Neil

AU - Lee, Steve S.

AU - Wong, Garrett B

AU - Gollapudi, Raghava R.

AU - Banares, Michelle

AU - Schatz, Richard A.

AU - Teirstein, Paul S.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide alone or eptifibatide plus UFH. Patients received aspirin 325 mg and clopidogrel 300 mg before the procedure. The primary end point was the Landefeld bleeding index. Secondary end points included the composite clinical outcome of in-hospital death, myocardial infarction, urgent target vessel revascularization, and Thrombolysis In Myocardial Infarction major bleeding, and a composite bleeding outcome of major, minor, and nuisance bleeding. The Landefeld bleeding index was significantly lower in the eptifibatide-only group compared with the eptifibatide-plus-UFH group (3.0 vs 3.9, p = 0.03). There was no significant difference in the composite clinical end point between groups (eptifibatide only 17% vs eptifibatide plus UFH 15%, p = 0.7). There was a trend toward a decrease in the composite bleeding end point in the eptifibatide-only compared with the eptifibatide-plus-UFH group (43% vs 56%, p = 0.10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications.

AB - Adjunctive glycoprotein IIb/IIIa inhibition decreases ischemic events after percutaneous coronary intervention (PCI) but is associated with increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, a thienopyridine, and a glycoprotein IIb/IIIa inhibitor without unfractionated heparin (UFH) would result in fewer bleeding complications and maintain efficacy in elective PCI. A total of 159 patients undergoing elective PCI were randomized to intraprocedural eptifibatide alone or eptifibatide plus UFH. Patients received aspirin 325 mg and clopidogrel 300 mg before the procedure. The primary end point was the Landefeld bleeding index. Secondary end points included the composite clinical outcome of in-hospital death, myocardial infarction, urgent target vessel revascularization, and Thrombolysis In Myocardial Infarction major bleeding, and a composite bleeding outcome of major, minor, and nuisance bleeding. The Landefeld bleeding index was significantly lower in the eptifibatide-only group compared with the eptifibatide-plus-UFH group (3.0 vs 3.9, p = 0.03). There was no significant difference in the composite clinical end point between groups (eptifibatide only 17% vs eptifibatide plus UFH 15%, p = 0.7). There was a trend toward a decrease in the composite bleeding end point in the eptifibatide-only compared with the eptifibatide-plus-UFH group (43% vs 56%, p = 0.10). In conclusion, during elective PCI, a strategy of aggressive antiplatelet therapy using aspirin, clopidogrel, and eptifibatide without anticoagulant therapy appears to decrease bleeding complications.

UR - http://www.scopus.com/inward/record.url?scp=34548634592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548634592&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.04.057

DO - 10.1016/j.amjcard.2007.04.057

M3 - Article

VL - 100

SP - 1099

EP - 1102

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -